OptimiTM-03.jpg
Optimi Health Signs Psilocybin Supply Agreement With New Zealand-Based Mātai Medical Research Institute
April 09, 2024 09:13 ET | Optimi Health Corp.
Optimi signs international natural psilocybin supply agreement with New Zealand-Based Mātai Medical Research Institute, on behalf of the Tū Wairua Project.
MicrosoftTeams-image (5).png
Drug Testing Market Size to Cross USD 15.7 Bn by 2033 with CAGR of 5.3% | Transparency Market Research
March 20, 2023 11:30 ET | Transparency Market Research
Wilmington, Delaware, United States, March 20, 2023 (GLOBE NEWSWIRE) -- According to the latest research by Transparency Market Research, the drug testing market was estimated to attain a global...
Bicycle after crash
Don't Use Drugs and Ride: Hospitals Treat Thousands of Drug-Related Bike Injuries Each Year
September 26, 2022 01:00 ET | Journal of Studies on Alcohol and Drugs
PISCATAWAY, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- From 2019 to 2020, more than 11,000 people who had been using drugs were treated in U.S. emergency departments for injuries that occurred while...
22157.jpg
Global Psychedelic Drugs Market Analysis Report 2022 Featuring AstraZeneca, COMPASS, Klarisana, F. Hoffmann-La Roche, Takeda Pharma, Dr. Reddy's Laboratories, Pfizer, Merck & Co., & Lundbeck
May 06, 2022 06:18 ET | Research and Markets
Dublin, May 06, 2022 (GLOBE NEWSWIRE) -- The "Global Psychedelic Drugs Market Size & Share to 2027" report has been added to ResearchAndMarkets.com's offering. Increase in prevalence of...
ACMT 2022 Symposium: Drug Science Meets Social Science: Substance Use, Pregnancy, and Baby
"Substance Use, Pregnancy, and Baby" Symposium Draws on Expertise of Medical, Social Science Professionals
February 07, 2022 09:00 ET | American College of Medical Toxicology
Phoenix, AZ, Feb. 07, 2022 (GLOBE NEWSWIRE) -- This one-day symposium draws on the expertise of professionals from multiple medical and social science fields to address drug/medication-related...